Mitos e verdades sobre o uso de antiplaquetários na intervenção percutânea

By Dr. Roberto Esporcatte.

roberto esporcatte

More articles by this author

Venus P-Valve: The valve and initial clinical worldwide experience

Por Dr. Alejandro Peirone.

FFR EM LESÕES SEQUENCIAIS E DOENÇA DIFUSA

Por Dr. Silvio Gioppato.  

Erros mais comuns na realização do FFR: como identificá-los e preveni-los

Por Dr. Fernando Mendes Sant’Anna.  

Análise Crítica do Estudo Leaders É o melhor stent que temos?

Por Dr. Esmeralci Ferreira.  

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long-Term Predictors of Valve Deterioration After TAVI

Transcatheter aortic valve implantation (TAVI) has become an innovative technology for the treatment of patients with severe aortic valve stenosis. Initially implemented in elderly...

Coronary access after TAVI with fourth- and fifth-generation Evolut valves: the EPROMPT-CA study

The expansion of transcatheter aortic valve implantation (TAVI) toward younger and lower-risk patients has increased the relevance of post-procedural coronary access. In this context,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...